Solara Active Pharma Sciences shares experienced a remarkable 16.3% surge to an intraday high of ₹759 on the NSE following the company's Q2FY27 earnings announcement. According to reports from Business Standard, the stock was trading near its 52-week high of ₹774 touched on September 15, 2026, while maintaining a 46.2% gain from levels of ₹513 at the end of July 2026. The stock had previously hit a 52-week low of ₹422 on March 30, 2026, and was trading 10.5% higher at ₹717 at 2:15 PM on Friday. As of October 16, 2026, the company has a total market capitalisation of ₹3,388.47 crore according to NSE data. The counter had a combined trading volume of around 42 lakh shares on the BSE and NSE during the session, reflecting strong investor interest in the company's turnaround story.
The pharmaceutical company achieved a significant financial turnaround in Q2FY27, posting a consolidated net profit of ₹28.59 crore compared to a loss of ₹9.29 crore in the same quarter of the previous year. As reported by Business Standard, total Q2 consolidated income grew by 33.1% year-on-year to ₹417.88 crore from ₹314.03 crore in Q2FY26. The reported consolidated earnings include those of the parent company and three subsidiaries: Shasun USA Inc, Synthix Global Pharma Solutions, and Chemsynth Laboratories Private Limited. According to the latest reports, the company's operating profit (EBITDA) jumped 7% to ₹77 crore compared to ₹35 crore in the corresponding quarter of the previous fiscal year, with EBITDA margin expanding to 18.47% in Q2 FY27 from 11% in Q2 FY26, despite continued input cost pressures. The company had reported a net loss of ₹7.41 crore in FY26, with total consolidated income in the last financial year standing at ₹1,375.14 crore.
On a half-yearly basis, Solara Active Pharma Sciences demonstrated exceptional growth with H1FY27 consolidated net profit zooming 10,559% or over 103-fold to ₹44.70 crore compared to ₹0.42 crore reported in H1FY26. According to the exchange filing reported by Business Standard, total income increased by 26.5% year-on-year to ₹802.17 crore from ₹634.16 crore in the six-month period. The company has achieved 59% of last fiscal's total income based on the FY27 numbers thus far, with total consolidated income in FY26 standing at ₹1,375.14 crore. As per the latest reports, the company posted highest quarterly EBITDA and PAT in the last five years. Given the FY27 numbers thus far, the company has achieved 59% of last fiscal's total income.
The company's commodity ibuprofen business showed significant improvement, with gross margin reaching around 36% and EBITDA margin improving to -0.2% in Q2 FY27, compared with -11.4% in Q1 FY27. According to Business Standard, revenue grew 21% over last year and 18% over last quarter, with the business now close to breakeven from a loss margin of 21% just two quarters ago. Managing Director and CEO Sandeep Rao noted that the base business continued to drive growth, with revenue, EBITDA and margin increasing despite higher raw material costs. The strategic review of the ibuprofen business, conducted with the board's advisors, has reached an advanced stage, with the firm expecting to share further updates with shareholders within the next 12 weeks.
The stock's performance significantly outpaced broader market indices, with Solara Active Pharma trading higher for the third straight month compared to the Sensex's 0.4% gain at 74,612 and the Nifty's 0.5% increase at 23,106. As reported by Business Standard, the counter had a combined trading volume of around 42 lakh shares on the BSE and NSE during the session, reflecting strong investor interest in the company's turnaround story. From the beginning of the year, Solara Activa Pharma Sciences shares have jumped 25%, with the stock surging 43.5% in the past six months and slipping just 1% over the past month.
